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Abstract
People with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD). Both pharmacological treatment 
and exercise are suggested in the management of CVD risk in RA. This study explored the effects of exercise and anti-TNF 
treatment on CVD risk in RA. Twenty RA patients (70% female, 50 (10) years) completed a 3-month exercise intervention 
and 23 RA patients (65% female, 54 (15) years) started anti-TNF treatment. Markers of disease activity, CVD risk, and 
vascular function were assessed before and after 3-months of intervention/treatment. Both exercise and anti-TNF treatment 
improved functional ability and fatigue, anti-TNF treatment was more successful in improving inflammation, disease activity, 
functional ability and pain. Exercise induced a reduction in overall CVD risk and improvement in vascular function, which 
was significantly different from anti-TNF treatment where no such changes were found. These findings showed that exercise 
and anti-TNF had differential effects on CVD risk in RA, and should be combined for optimal CVD risk reduction. Whereas 
anti-TNF treatment is likely to impact on CVD risk through reducing the systemic inflammatory load, exercise should be 
recommended to people with RA as an effective self-management strategy to reduce CVD risk further. Once RA patients 
have responded successfully to anti-TNF treatment, increasing exercise should be encouraged to reduce the risk for CVD. 
Thus, supporting exercise programmes when the disease is controlled, is likely to enhance the uptake and the maintenance 
of exercise, which will result in additional benefits to cardiovascular health and wellbeing in people with RA.
Keywords Rheumatoid arthritis · Exercise · Anti-TNF treatment · Cardiovascular disease risk
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disease 
which is characterised by high-grade systemic inflamma-
tion, swollen and painful joints [1]. The impact of RA is not 
restricted to the joints, patients often suffer from increased 
fatigue and depression [2], which influence psychologi-
cal wellbeing. Patients with RA are also at increased risk 
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for cardiovascular disease (CVD) compared to the general 
population, with up to 50% of patients with RA dying as a 
result of cardiovascular complications [3]. The reasons for 
this increased risk are not fully understood, but both high-
grade systemic inflammation and traditional CVD risk fac-
tors, which are prevalent in RA (e.g. hypertension [4] and 
obesity [4]), are thought to contribute to this [3, 6]. Indeed, 
a recent large international cohort study indicated that 70% 
of the CVD events could be attributed to CVD risk fac-
tors and RA-disease-related factors [7]. It is therefore not 
surprising that the European League against Rheumatism 
(EULAR) recommendations for CVD risk management in 
RA now include both control of disease activity through 
medication and CVD-risk reducing lifestyle interventions 
such as exercise [8].
Exercise is an effective lifestyle intervention to reduce 
CVD risk in the general population as well as in people with 
an already increased risk. Exercise can also reduce the risk 
for recurrence of cardiac events in those with established 
CVD [9, 10]. Exercise can achieve these benefits through 
improvements in individual CVD risk factors, such as low-
ering blood pressure and improving lipid profile. However, 
the reduction in CVD risk cannot be explained solely by a 
reduction in these individual risk factors, the effects of exer-
cise on the vasculature have been suggested to also contrib-
ute to the reduction in CVD risk [11]. Despite the abundance 
of information regarding the benefits of exercise for CVD 
risk in the general population, exercise has only recently 
been shown to improve overall CVD risk and endothelial 
function in RA [12, 13]. The potential of exercise to reduce 
CVD risk in RA is underscored by including exercise as a 
management strategy of CVD risk in RA by EULAR [8].
Anti-tumor necrosis factor-α (anti-TNF) is an effective 
treatment to reduce inflammation and overall disease activ-
ity in RA. There is strong evidence from meta-analyses that 
anti-TNF treatment is associated with a reduction in risk 
for acute cardiovascular events in RA [14, 15]. The exact 
mechanisms through which anti-TNF can improve CVD risk 
are not known. Even though the treatment specifically targets 
the cytokine TNF, a reduction in TNF reduces other inflam-
matory markers through various signalling pathways [16], 
which has been suggested to reduce the CVD risk [1, 14]. 
Other factors which have been proposed to contribute to the 
reduced CVD risk include improvements in functional abil-
ity, less need for medication with an increased risk for CVD 
(e.g. corticosteroids [14]), and improvement in endothelial 
function [6].
In sum, exercise and pharmacological treatments effective 
in reducing inflammation have both been shown to reduce 
CVD risk in RA. However, it is not known how these dif-
ferent treatments compare to each other. Given the potential 
differences in mechanisms underlying changes following 
exercise and pharmacological treatment, it is likely that these 
interventions have differential effects. To our knowledge, the 
secondary analyses presented here are the first report com-
paring the effects of exercise with the effects of anti-TNF 
treatment on markers of disease activity, CVD risk factors, 
and vascular function in RA. Getting a better understanding 
of the effects of these different treatments can help inform 
clinical practice regarding effective strategies to reduce CVD 
risk in this population.
Methods
Participants
All participants were recruited from the Dudley Group 
NHS Foundation Trust Rheumatology outpatient clinics 
for two separate studies. Twenty participants were recruited 
to participate in an exercise intervention (Registered trial: 
ISRCTN50861407). Twenty-three participants who were 
about to start anti-TNF treatment on clinical indication were 
recruited into a 3-month prospective study. Both studies 
complied with the Declaration of Helsinki, were approved 
by local research ethics committees (exercise: Black Coun-
try Research Ethics Committee, anti-TNF: Birmingham East 
North and Solihull Research Ethics Committee), and all par-
ticipants provided written informed consent. All participants 
met the RA diagnosis according to revised ACR criteria [17] 
and none of the participants had established CVD (e.g. had 
experienced cardiac event). Additional exclusion criteria 
for those in the exercise intervention were participating in 
structured exercise in the previous 6 months, comorbidities 
incompatible with exercise according to the American Col-
lege of Sports Medicine [18]. All participants completed 
assessments at pre-intervention baseline and at three months. 
Detailed information regarding participants, interventions 
and assessments is provided elsewhere [19, 20].
Exercise programme
Participants in the exercise intervention completed an exer-
cise tolerance test to determine their maximal aerobic capac-
ity  (VO2max). The exercise programme was developed based 
on the participant’s ability and preferences using apparatus 
such as treadmills, cycle, hand and rowing ergometers. Par-
ticipants were asked to exercise three times per week for 
1 h. Two sessions of this individualised programme were 
conducted in a supervised setting and one unsupervised ses-
sion at home. Each sessions started with 10 min warm up, 
followed 30–40 min where they completed three circuits at a 
heart rate corresponding to 70% of their  VO2max, and ended 
with a 5–10 min cool down [19].
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Anti‑TNF treatment
Fifteen participants started on adalimumab, six participants 
on etanercept, and two participants on infliximab. None of 
the participants had previously received any other biologic 
drugs, including anti-TNF treatment. Participants did not 
change other medication during the course of the study [20]. 
Patients continued treatment with other drugs during the 
study period, including methotrexate (70%), cyclooxygenase 
II inhibitors (4%), nonsteroidal anti-inflammatory drugs 
(26%), prednisolone (26%), anti-hypercholesterolemic drugs 
(18%), and antihypertensive drugs (22%).
Assessments
Disease activity
A range of clinical and self-reported measures of disease 
activity was used. Disease activity was assessed with Dis-
ease Activity Score (DAS28 [21]), taking into account num-
ber of painful and swollen joints as well as overall health 
in the previous week. Functional ability was assessed with 
the Stanford Health Assessment Questionnaire (HAQ [22]). 
Systemic inflammation was assessed with high-sensitivity 
C-reactive protein (CRP), erythrocyte sedimentation rate 
(ESR) and fibrinogen using the standardised laboratory 
protocols. Fatigue was assessed with the multidimensional 
assessment of fatigue [23]. Participants were asked to rate 
their overall pain in the previous week using a visual ana-
logue scale ranging from 0 ‘no pain at all’ to 100 ‘worst 
pain ever’.
Cardiovascular risk measures
Blood pressure and serological markers of CVD risk includ-
ing cholesterol, triglycerides, high-density lipoproteins 
(HDL) and insulin sensitivity (homeostasis model assess-
ment—HOMA and Quantitative insulin-sensitivity check 
index—QUICKI), were assessed. Global CVD risk was 
estimated using the Framingham risk score [24].
Vascular function
Large vessel endothelium-dependent [flow-mediated dilata-
tion (FMD)] and endothelium-independent [sublingual glyc-
eryl-trinitrate (GTN)] function was assessed using high-res-
olution ultrasonography. Laser Doppler imaging (Moor LDI 
2 SIM: Moor Instruments, Ltd Devon, UK) with iontophore-
sis of acetylcholine (ACh) and sodium-nitroprusside (SNP) 
was used to measure endothelium-dependent and endothe-
lium-independent microvascular function, respectively [25].
Statistical analyses
Mixed linear modeling was used to explore within- and 
between participant changes in markers of disease activity, 
CVD risk and vascular function separately. This approach 
was chosen over repeated measures ANOVA as it does not 
assume sphericity of the data, can process non-normally dis-
tributed data and deal with occasional missing data [26]. The 
within-person level was Time (level 1) and between-person 
level was participant (level 2). Group (anti-TNF and exer-
cise) was a predictor variable at level 2, with anti-TNF as the 
reference group. Time by Group interaction effects were cal-
culated to explore differences in changes over time between 
groups. Sex and mean centered age were entered at level 2 
as covariates. In interpreting the findings, it is worth noting 
that the Time × Group interactions test whether the rate of 
change from baseline to 3 months was equivalent across the 
two groups for a female of average age. All analyses were 
conducted using IBM SPSS, version 22.
Results
Participant characteristics at baseline
There were no significant differences between the groups 
with regards to age (exercise: 50 [10], anti-TNF: 54 
[15] years), disease duration (exercise: 6 [1–25], anti-TNF: 
7 [2–43] years) or sex (exercise: 70% women, anti-TNF: 65% 
women). Baseline levels of markers of disease activity, CVD 
risk factors, and vascular function are reported in Table 1. 
As expected, participants starting anti-TNF had higher base-
line levels of disease activity which reached significance 
for DAS28 and fibrinogen. In addition, baseline levels of 
functional ability, fatigue and pain were also poorer in par-
ticipants in the anti-TNF group. CVD risk indicators were 
not significantly different, but large vessel endothelium-
independent function was poorer in the exercise group at 
baseline.
Effects of exercise and anti‑TNF treatment
The effects of exercise and anti-TNF treatment are presented 
in Table 1. Anti-TNF treatment was successful at improv-
ing disease-related markers, whereas after 3 months of 
exercise only functional ability and fatigue were improved. 
Significant Time by Group interaction effects were found 
for Fibrinogen, DAS28, HAQ, and pain, indicating that anti-
TNF treatment induced greater improvements in these meas-
ures than exercise. Given the baseline differences in most of 
the disease-related measures, it is important to highlight that 
 Rheumatology International
1 3
after 3 months of anti-TNF treatment disease-related mark-
ers were similar to the baseline values of the exercise group.
Anti-TNF treatment did not induce many changes in CVD 
risk factors, with the exception of an increase in choles-
terol and a reduction in diastolic blood pressure. In contrast, 
exercise induced a reduction in Framingham risk score and 
improvement in vascular function, which were not changed 
in response to anti-TNF treatment (significant Time by 
Group interaction effects, p’s < 0.05, see Table 1).
Discussion
The current study showed that exercise and anti-TNF treat-
ment had differential effects on CVD risk in people with 
RA. Exercise was more successful at improving overall CVD 
risk and vascular function compared to anti-TNF treatment 
in RA. Whereas both exercise and anti-TNF treatment 
improved functional ability and fatigue, anti-TNF treatment 
was more successful in improving inflammation, DAS28, 
functional ability and pain.
At baseline, people starting anti-TNF treatment had 
higher disease activity, fatigue and pain as well as lower 
functional ability compared to the participants starting the 
exercise programme. This finding is not surprising, given 
that anti-TNF treatment is recommended by NICE only 
if patients experience high disease activity and have not 
responded to a combination of conventional disease-mod-
ifying antirheumatic drugs. We also know from our own 
experience that RA patients who are volunteering to partici-
pate in an exercise study tend to have relatively well con-
trolled disease activity. The improvements in disease-related 
measures following anti-TNF provide evidence for the effec-
tiveness of this treatment in controlling disease activity. As 
Table 1  Estimated means (SE) for baseline and 3 months for the exercise group and the anti-TNF group
All values are estimated means for a female with average age. All analyses were conducted with age and sex as covariates
DAS28 disease activity score in 28 joints, HAQ health assessment questionnaire, HDL high density lipids, HOMA homeostasis model assess-
ment, QUICKI quantitative insulin-sensitivity check index, FMD flow-mediated dilatation, GTN glyceryl trinitrate, ACh acetyl choline, SNP 
sodium nitroprusside
*: significantly different from baseline
# : significantly different from baseline exercise
a no covariates used for the analyses
Exercise Anti-TNF Time× group interaction
Baseline 3 months Baseline 3 months
Disease related measures
C-reactive protein (mg/l) 6.96 (3.22) 3.30 (4.12) 13.05 (2.39) 7.15 (2.70)* t(41.5) = 0.54, p = .590
Erythrocyte Sedimentation Rate (mmhr) 19.68 (6.38) 18.86 (7.37) 27.21 (4.65) 27.88 (4.81) t(38.7) = -0.20, p =.841
Fibrinogen (g/L) 4.11 (0.29) 4.02 (0.27) 5.05 (0.21)# 4.33 (0.17)* t(36.1) = 2.36, p =.024
DAS28 3.33 (0.34) 2.93 (0.33) 4.31 (0.26)# 2.92 (0.26)* t(39.6) = 3.02, p =.004
HAQ 1.41 (0.23) 1.27 (0.19)* 2.12 (0.17)# 1.30 (0.13)* t(37.9) = 2.41, p =.021
Fatigue 22.31 (3.86) 15.54 (3.92)* 35.78 (2.85)# 21.72 (2.60)* t(38.6) = 1.86, p =.071
Pain (out of 100) 36.59 (8.85) 37.82 (9.78) 64.00 (6.49)# 37.72 (6.50)* t(38.5) = 2.81, p =.008
CVD risk factors
Body mass index (kg/m2) 28.81 (1.77) 28.64 (0.29) 30.22 (1.41) 30.34 (0.20) t(38.0) = 21.39, p =.324
Framingham risk  scorea 5.50 (1.87) 4.05 (0.69)* 5.79 (1.34) 5.74 (0.50) t(36.1) = -2.04, p =.049
Systolic blood pressure (mm Hg) 130.61 (3.90) 125.81 (3.40) 126.88 (2.98) 119.19 (2.32) t(41.0) = 0.85, p =.401
Diastolic blood pressure (mm Hg) 77.96 (2.24) 75.06 (2.06) 79.15 (1.71) 74.08 (1.40)* t(41.0) = 1.05, p =.298
Cholesterol (mmol/L) 5.17 (0.32) 5.12 (0.18) 4.88 (0.24) 4.97 (0.11)* t(36.0) = -0.82, p =.417
Triglycerides (mmol/L) 1.31 (0.22) 1.26 (0.22) 1.27 (0.17) 1.48 (0.14) t(38.0) = -1.18, p =.245
HDL (mmol/L) 1.50 (0.09) 1.53 (0.05) 1.56 (0.07) 1.55 (0.03) t(36.7) = 0.81, p =.424
HOMA 1.79 (1.22) 2.76 (1.50) 2.59 (0.79) 1.97 (0.92) t(34.8) = 1.06, p =.295
QUICKI 0.34 (0.01) 0.34 (0.01) 0.35 (0.01) 0.34 (0.01) t(26.9) = 0.87, p =.867
Vascular function
Large vessel endothelium-dependent (FMD%) 7.55 (2.24) 18.34 (2.59)* 8.93 (1.62) 11.50 (1.67) t(37.7) = 3.17, p =.003
Large vessel endothelium-independent (GTN%) 18.81 (2.18) 27.11 (2.01)* 23.43 (1.60)# 24.67 (1.34) t(35.9) = 3.51, p =.001
Microvascular endothelium-dependent (ACh%) 331 (72) 426 (83) 301 (50) 331 (49) t(34.1) = 0.79, p =.437
Microvascular endothelium-independent (SNP%) 239 (57) 434 (52)* 230 (41) 239 (31) t(34.4) = 3.57, p =.001
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participants starting anti-TNF treatment had higher levels 
of disease activity, there was also more opportunity for 
improvement in this group, which could contribute to the 
significant Time by Group interaction effects. Indeed, fol-
lowing anti-TNF treatment, disease-related measures were 
similar compared to the baseline levels of the patients in 
the exercise intervention. It is important to note that most 
disease-related measures also improved with exercise, how-
ever, these improvements were only statistically significant 
for functional ability and fatigue. Both fatigue and functional 
ability are commonly mentioned barriers to exercise in peo-
ple with RA [27], however, in line with previous research 
[28, 29], these findings show that exercise can improve these 
important patient-focussed measures. Thus, it is important 
for exercise programmes for people with RA to include edu-
cation about the health benefits of exercise as well as support 
to overcome barriers to exercise.
Despite no significant changes in individual risk factors, 
global CVD risk was significantly reduced following exer-
cise compared to anti-TNF treatment. Most individual risk 
factors showed an improvement following exercise, albeit 
not statistically significant. Together, these changes resulted 
in an improvement of global CVD risk, and provide evidence 
that only 3 months of exercise already results in a significant 
reduction in the risk for cardiovascular disease in RA. Given 
that anti-TNF treatment has been shown to reduce the risk 
for acute cardiovascular events [14, 15], the lack of changes 
in global CVD risk following anti-TNF was not expected. 
Greater CVD risk reduction has been associated with longer 
duration of anti-TNF treatment [30]. Thus, it is possible that 
3 months of treatment is not sufficient to reduce global CVD 
risk, and longer term treatment is needed. Another possibil-
ity is that the CVD risk reduction following anti-TNF treat-
ment is due to a reduction in disease-related inflammation, 
which is not incorporated in the global CVD risk calculator 
used in the current study.
The benefits of exercise on the vasculature are well-
known, and it has been suggested that the increases in shear 
stress during regular exercise enhance structural changes 
as well as signalling pathways and inflammatory processes 
within the vascular wall associated with vascular function 
[11, 31, 32]. Less is known about the effects of anti-TNF 
treatment on the vasculature. In vivo assessments of vascular 
function following successful treatment provide no strong 
evidence for direct associations between systemic inflam-
mation and vascular function [33]. Vascular wall inflamma-
tion was significantly higher in those treated with anti-TNF 
compared to DMARDs, despite both groups achieving low-
grade systemic inflammation indicative of remission [34]. 
This discrepancy between local and systemic effects of TNF 
on vascular function has also been reported in experimen-
tal studies [35]. Thus, it is likely that the improvements in 
in vivo vascular function following exercise are due to lower 
levels of vascular wall inflammation, which is not achieved 
following anti-TNF treatment, despite an anti-TNF-induced 
reduction in systemic inflammation.
The differential benefits of exercise and anti-TNF of this 
study have important implications for the timing of encour-
agement for people with RA to become more physically 
active to reduce their CVD risk. Pain, fatigue and functional 
ability are commonly mentioned barriers to exercise and 
physical activity [27]. It is therefore not surprising that peo-
ple with RA have indicated that once their disease activity is 
controlled, they are more likely to engage with behavioural 
interventions to reduce CVD risk, such as exercise [36–38]. 
Observational studies show that following successful treat-
ment of disease activity in RA self-reported physical activ-
ity was increased [39] and medication-induced improve-
ments in disease activity were related to physical activity 
increases [40]. Thus, providing support by offering exer-
cise programmes when the disease is controlled, is likely to 
enhance the uptake and the maintenance of exercise, which 
as the current study reveals will result in additional benefits 
to their CVD risk and vascular function, as well as func-
tional ability and fatigue.
The baseline differences between the two groups are a 
limitation of the current study, a randomised controlled 
trial would allow for a more stringent comparison between 
exercise and anti-TNF treatment. However, for ethical rea-
sons, it is not possible to withhold pharmacological treat-
ment from those who need it based on clinical assessment. 
It should also be acknowledged that the interventions were 
exclusive; participants either started exercise intervention or 
anti-TNF treatment and it is therefore not known what the 
effect would be of starting exercise and anti-TNF treatment 
simultaneously. The relatively brief follow-up period could 
be an explanation for the lack of effects of anti-TNF on CVD 
risk, particularly given that CVD risk reduction is related 
to the duration of the exposure to anti-TNF [30]. Neverthe-
less, other studies have reported transient improvements in 
endothelial function and some CVD risk factors following 
anti-TNF [33]. Even though endothelium-dependent micro-
vascular function improved following exercise, this did not 
reach statistical significance, which could be due to some 
missing data for this measurement. Therefore, this will need 
to be confirmed in a larger cohort.
In summary, exercise and anti-TNF treatment have dif-
ferential effects on cardiovascular health in people with 
RA. Exercise induced a reduction in overall CVD risk and 
improvement in vascular function, while anti-TNF treatment 
was better at improving disease-related measures. Thus, 
whereas anti-TNF treatment is likely to impact on CVD risk 
through reducing the systemic inflammatory load, exercise 
should be recommended to people with RA as an effec-
tive self-management strategy to reduce CVD risk further. 
Given that both disease-related factors and CVD risk factors 
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have been shown to contribute to CVD events in RA [7], 
the combination of exercise and anti-TNF treatment might 
provide the best protection for CVD in RA. Pain, fatigue 
and functional ability are commonly mentioned barriers to 
exercise and physical activity [27], and observational stud-
ies already showed increases in physical activity following 
successful treatment of disease activity [39, 40]. Thus, sup-
porting exercise programmes for people with RA when the 
disease is controlled, is likely to enhance the uptake and 
the maintenance of exercise, which will result in additional 
benefits for cardiovascular health and wellbeing.
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